Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • JAK
    (3)
  • Apoptosis
    (2)
  • BTK
    (2)
  • Akt
    (1)
  • Antifection
    (1)
  • ERK
    (1)
  • Endogenous Metabolite
    (1)
  • Estrogen/progestogen Receptor
    (1)
  • FAK
    (1)
  • Others
    (20)
Filter
Search Result
Results for "

synergistic effect

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    37
    TargetMol | Inhibitors_Agonists
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Natural Products
    8
    TargetMol | Natural_Products
  • Cell Research
    1
    TargetMol | Inhibitors_Agonists
Rufigallol
AI3 00865, AI3-00865, AI300865
T2616882-12-2In house
Rufigallol (AI3-00865) is an electron-deficient disk-shaped molecule with six hydroxyl groups and is a good unit for inducing the formation of DLC from non-planar AIE molecules, an anthraquinone derivative.Rufigallol induces the acquisition of DLC properties, while the introduction of TPE groups gives the molecular structure good fluorescence in the aggregated state.The remarkable synergistic in vitro antimalarial effect, in vivo with vitamin C and ketones was synergistic and showed antimalarial activity.
  • Inquiry Price
6-8weeks
Size
QTY
TargetMol | Inhibitor Sale
JAK3/BTK-IN-2
T98132674036-93-0In house
JAK3 BTk-in-2 is a potent JAK3 BTK inhibitor. JAK3 BTk-in-2 inhibits both BTK and JAK3, which are two important targets IN autoimmune diseases. JAK3 BTk-in-2 simultaneously inhibits the BTK JAK3 signaling pathway, showing a synergistic effect. JAK3 BTk-in-2 has the potential to treat diseases associated with abnormal JAK3 and BTK activity.
  • Inquiry Price
6-8 weeks
Size
QTY
JAK3/BTK-IN-1
T98142674036-91-8In house
JAK3 BTk-in-1 is a dual JAK3 BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important targets in autoimmune diseases. JAK3 BTk-in-1 simultaneously inhibited the BTK JAK3 signaling pathway, showing a synergistic effect. JAK3 BTK-in-1 is a potential compound for the treatment of immune-related diseases, such as autoimmune diseases, certain types of cancer (including lymphoma and leukemia), and other diseases that may be characterized by an unbalanced immune response.
  • Inquiry Price
6-8 weeks
Size
QTY
trans-Cyclohexane-1,2-diol
trans-1,2-Cyclohexanediol
T47631460-57-7
trans-Cyclohexane-1,2-diol (trans-1,2-Cyclohexanediol) has a synergistic retardation effect on percutaneous absorption and penetration of metronidazole (MTZ).
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Brusatol
(+)-Brusatol, NSC 172924
TQ021114907-98-3
Brusatol (NSC-172924) is a natural product isolated from the Brucea javanica plant. It inhibits Nrf2.
  • Inquiry Price
Size
QTY
ZG-2033
T2032292685739-28-8
ZG-2033 (Compound 26) is an orally active HIF-2α agonist that exhibits nanomolar activity (EC50 = 490 nM) in a luciferase reporter assay. It demonstrates an anti-anemic effect and shows synergistic effects with AKB-6548 in anemia, making it useful for the study of renal anemia.
  • Inquiry Price
Size
QTY
HPK1-IN-54
T2035803048537-48-7
HPK1-IN-54 (Compound 16) is a potent inhibitor of HPK1 (hematopoietic progenitor kinase 1), enhancing T cell activation and proliferation by blocking HPK1 activity to exert antitumor effects. It has an IC50 of 2.67 nM for HPK1, showing excellent selectivity over the MAP4K family (>100-fold) and other selected kinases (>300-fold). HPK1-IN-54 exhibits moderate in vivo clearance and reasonable oral exposure in both mice and rats. Additionally, in the CT26 mouse colon cancer model, HPK1-IN-54 demonstrates significant antitumor activity and shows a synergistic effect when combined with anti-PD-1 therapy. HPK1-IN-54 holds promise for research in the field of immunology.
  • Inquiry Price
Size
QTY
AKT-IN-24
T204133
AKT-IN-24 (Compound M17) is an allosteric inhibitor of AKT exhibiting antitumor activity. In combination with Trametinib, it targets the AKT mTOR and MEK ERK signaling pathways while inhibiting epithelial-mesenchymal transition, resulting in a synergistic suppression effect on TNBC. This combination promotes apoptosis and inhibits cell proliferation and migration.
  • Inquiry Price
Size
QTY
Conteltinib tetrahydrochloride
CT-707 tetrahydrochloride, Conteltinib tetrahydrochloride
T204589
Conteltinibtetrahydrochloride (CT-707 tetrahydrochloride) is the tetrahydrochloride form of Conteltinib. It acts as an inhibitor for FAK (IC50=1.6 nM), ALK, and Pyk2. When used in combination with Cabozantinib, Conteltinib tetrahydrochloride exhibits a synergistic antitumor effect.
  • Inquiry Price
7-10 days
Size
QTY
JAK-IN-40
T205062
JAK-IN-40 (Compound 46) is an inhibitor of JAK, effectively targeting JAK1, JAK2, and JAK3 with IC50 values of 0.022, 0.759, and 1.601 μM, respectively. It reduces the phosphorylation of STAT3 and inhibits the proliferation of cancer cells Ba F3 and JAK1-TEL Ba F3 with GI50 values of 0.614 μM and 0.193 μM. JAK-IN-40 arrests cell cycle progression at the G2 M phase in H1975 and H2087 cells, leading to apoptosis. Additionally, JAK-IN-40 exhibits a synergistic anti-tumor effect when used in combination with Osimertinib.
  • Inquiry Price
Size
QTY
USP1-IN-11
T205601
USP1-IN-11 (compound 38-P2) is a selective, reversible, and non-competitive inhibitor of USP1 (Ubiquitin-specific protease 1). It promotes the activation of the DDR (DNA damage repair) pathway, inducing cell cycle arrest and apoptosis, thereby inhibiting cell viability. USP1-IN-11 increases the sensitivity of cells resistant to Olaparib and shows synergistic effects with Andrographolide in cancer cells with normal BRCA function. In the MDA-MB-436 xenograft model, USP1-IN-11 exhibits a significant dose-dependent antitumor effect.
  • Inquiry Price
Size
QTY
cmp3a
CMP-3a, CMP 3a
T270522225902-88-3
CMP3a is a NEK2 kinase inhibitor. CMP3a efficiently attenuated GBM growth in a mouse model and exhibited a synergistic effect with radiotherapy. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase E
  • Inquiry Price
8-10 weeks
Size
QTY
Cgp 43182
Cgp-43182,Cgp43182
T30831150379-37-6
CGP 43182 is an effective inhibitor of group IIA secretory phospholipase A2 (Group IIA sPLA2) activity in vitro, which can be used to prevent the synergistic effect of pro-inflammatory genes stimulated by cytokines mediated by NFkappaB.
  • Inquiry Price
6-8 weeks
Size
QTY
DNA-PK-IN-3
T617512734846-19-4
DNA-PK-IN-3 is a highly potent inhibitor of DNA-PK that exerts a synergistic effect with radiotherapy and chemotherapy, enhancing therapeutic outcomes and significantly inhibiting tumor growth. Additionally, it demonstrates remarkable efficacy in reducing damage to normal cells, thereby minimizing adverse side effects, making it a compound of great potential for cancer research applications[1].
  • Inquiry Price
6-8 weeks
Size
QTY
JAK3/BTK-IN-5
T621532673196-75-1
JAK3 BTK-IN-5 is a potent inhibitor of JAK3 BTK, crucial targets in autoimmune diseases. Inhibiting the BTK JAK3 signaling pathway simultaneously has a synergistic effect, enhancing its potential research value for JAK3 kinase and or BTK-related diseases.
  • Inquiry Price
6-8 weeks
Size
QTY
JAK3/BTK-IN-3
T622342674036-98-5
JAK3 BTK-IN-3 is a potent inhibitor of JAK3 BTK and targets two important pathways in autoimmune diseases. The simultaneous inhibition of the BTK JAK3 signaling pathway exhibits a synergistic effect, highlighting JAK3 BTK-IN-3's potential for investigating JAK3 kinases and or BTK-related diseases.
  • Inquiry Price
10-14 weeks
Size
QTY
JAK3/BTK-IN-4
T625532673196-38-6
JAK3 BTK-IN-4 is a potent inhibitor of JAK3 BTK, targeting critical pathways in autoimmune diseases. The simultaneous inhibition of the BTK JAK3 signaling pathway exerts a synergistic effect, making JAK3 BTK-IN-4 a promising therapeutic candidate for JAK3 kinase and or BTK-related diseases.
  • Inquiry Price
10-14 weeks
Size
QTY
Ki23057
T69162516523-31-2
Ki23057 is a a FGFR2 inhibitor, which enhances the chemosensitivity of drug-resistant gastric cancer cell lines when used in combination with chemotherapeutic drugs. Ki23057 might be therapeutically promising for treating drug-resistant gastric cancer cells, especially when used in combination with SN38, PTX, or VP16. The apoptosis process might be the main mechanism underlying the synergistic effect of these combinations. The ERCC1 and p53 genes may play an integral role in the synergism between Ki23057 and chemotherapeutic agents in drug-resistant cell lines. (source: Cancer Lett. 2011 Aug 1;307(1):47-52).
  • Inquiry Price
6-8 weeks
Size
QTY
L0909
T699352085271-43-6
L0909 is an orally available inhibitors of Hepatitis C virus with a novel mechanism of action (EC50 = 0.022 μM, SI > 600). L0909 could block HCV replication by acting on the HCV entry stage. The high sensitivity to clinical resistant HCV mutants and synergistic effect with clinical drugs were observed for this compound. L0909 as a promising HCV entry inhibitor for single or combinational therapeutic potential.
  • Inquiry Price
6-8 weeks
Size
QTY
AS2575959
T703731616871-34-1
AS2575959 is a novel GPR40 agonist, exhibiting glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion.
  • Inquiry Price
10-14 weeks
Size
QTY
CHS-828 nicotinate
T713611160589-73-0
CHS-828 nicotinate is a CHS-828 salt with Nicotinic acid.. CHS-828 also known as GMX-1778, is a potent and selective NAMPT inhibitor. CHS-828 inhibits cellular synthesis of NAD. CHS 828 kill tumour cells by inhibiting the nuclear factor-kappaB translocation but unlikely through down-regulation of proteasome. CHS 828 has shown promising anticancer activity in experimental tumor models and primary cultures of cancer cells from patients. CHS 828 showed a synergistic effect with melphalan in 67%, doxorubicin in 47%, etoposide in 38% and Ara-C in 14% of AML samples.
  • Inquiry Price
6-8 weeks
Size
QTY
(-)SHIN2
T73358
(+)SHIN2, an isomer of (-)SHIN2, is an inhibitor of serine hydroxymethyltransferase (SHMT) with antileukemic effects and shows synergistic activity with Methotrexate in in vivo xenotransplantation models [1].
  • Inquiry Price
6-8 weeks
Size
QTY
18:0 EPC chloride
T74318328268-13-9
18:0 EPC chloride, a synthetic cationic phospholipid, significantly enhances eugenol's inactivation effect on Escherichia coli [1] when used at critical synergistic concentrations ranging from 2.34 to 2.93 μM.
  • Inquiry Price
Size
QTY
Dehydrobruceine B
T7548553730-90-8
Dehydrobruceine B, a quassinoid isolated from Brucea javanica, demonstrates a synergistic effect with Cisplatin in inducing apoptosis through the mitochondrial pathway. It enhances the expression of apoptosis-inducing factor (AIF) and Bax while inhibiting Keap1-Nrf2 [1].
  • Inquiry Price
Size
QTY